ストックスクリーナーアプリを入手
0.513
14.25%
0.064
Aprea Therapeutics Inc (APRE) 最新ニュース
APRE 8-K & SEC FilingsYahoo Finance - Yahoo! Finance Canada
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Atrium Therapeutics Announces $50 Million Private Placement - Yahoo Finance
APRE: Aprea Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Aprea Therapeutics to Present at October Conferences - The Manila Times
Aprea Therapeutics, Inc. (APRE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Aprea Puts Cancer Drug Pipeline Before Investors - MyChesCo
Aprea Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
Dose Escalation, Combination Strategy Keep Aprea Ahead In Its Oncology Trials - Clinical Leader
Aprea Therapeutics Inc (APRE:UR): Stock Price, Quote and News - bnnbloomberg.ca
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Expands Patent Portfolio for Precision Oncology Programs - minichart.com.sg
Aprea Therapeutics reports patent portfolio of 58 patents - Investing.com
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com Canada
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com India
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - manilatimes.net
Aprea Therapeutics reports patent portfolio of 58 patents By Investing.com - Investing.com UK
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - marketscreener.com
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - Barchart.com
Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ) - Seeking Alpha
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Expansion Phase - vinanet.vn
Aprea (APRE) Stock: Advances 1.19% to $0.64 in the Latest Reading; Market Levels: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateHigh Volume Node - vinanet.vn
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateOne-Time Loss Impact - careplusvn.com
Aprea (APRE) Q1 2026 Earnings: EPS Prints Above Forecast in the Latest Session; Trading Move: The Stock Gains 1.19% in the Current UpdateEarnings Weakness Phase - dars.gov.et
Aprea (APRE) Q1 2026 Scorecard: EPS Exceeds Its Estimate in the Latest Session; Stock Move: The Market Price Declines 2.61% at the CloseInterim Report - careplusvn.com
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotChandelier Stop - vinanet.vn
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotLow Risk Entry Stocks - dars.gov.et
Aprea (APRE) Technical Snapshot: Slides 2.03% to $0.68 for the Current Session; Session Range View: Price Remains Between $0.65 Support and $0.71 Resistance under the Current SnapshotHigh Dividend Factor - www.dars.gov.et
APRE Q1 2026 Earnings: Narrower-than-Expected Loss Signals Disciplined ExecutionEarnings Recovery Stocks - Vinanet
Aprea Expands Cancer Trial as APR-1051 Shows Early Activity - MyChesCo
Aprea Therapeutics (APRE) Edges Higher by 1.34% as Shares Hover Above Key SupportStrangle Setup - vinanet.vn
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Mid Cap Momentum - vinanet.vn
Oppenheimer Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Aprea Therapeutics (APRE) Consolidates Near Support as Shares Dip 1.76%Quote Data - dars.gov.et
Aprea Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Aprea Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Aprea Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Nigeria
APRE: APR-1051 demonstrates promising early efficacy and safety, driving a biomarker-focused oncology pipeline - TradingView
Aprea Therapeutics advances APR-1051 oncology pipeline progress - TipRanks
Form 8K Aprea Therapeutics Inc For: 12 August - Investing.com India
Aprea Therapeutics 2Q 2026: Revenue $0 Net loss $(3.59M), EPS $(0.07) — 10-Q Summary - TradingView
Form 8K Aprea Therapeutics Inc For: 12 August By Investing.com - Investing.com Canada
Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan
Aprea Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Aprea Therapeutics Reports $3.6 Million Q2 Net Loss - Quiver Quantitative
Aprea Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds - Yahoo Finance
Avere Therapeutics Announces $500 Million Private Placement to Support Development of Once-Weekly Oral IL-23 Therapy AVR-001 - finance.yahoo.com
5.91%
2.85%
大文字化:
|
ボリューム (24 時間):